Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Acta Crystallogr D Struct Biol ; 79(Pt 7): 666-667, 2023 Jul 01.
Article in English | MEDLINE | ID: mdl-37338421

ABSTRACT

Equations in Sections 2.3 and 2.4 of the article by Afonine et al. [Acta Cryst. (2013). D69, 625-634] are corrected.

2.
Mol Oncol ; 16(18): 3213-3219, 2022 09.
Article in English | MEDLINE | ID: mdl-36128609

ABSTRACT

Many cancers show an increase in incidence with age, and age is the biggest single risk factor for many cancers. However, the molecular basis of this relationship is poorly understood. Through a collection of review articles, our thematic issue discusses the link between aging and cancer in aspects including somatic mutations, proteostasis, mitochondria, metabolism, senescence, epigenetic regulation, immune regulation, DNA damage, and telomere function.


Subject(s)
Epigenesis, Genetic , Neoplasms , Aging/genetics , Aging/metabolism , Humans , Mitochondria/genetics , Mitochondria/metabolism , Neoplasms/genetics , Neoplasms/metabolism , Telomere/genetics
3.
Oncogene ; 37(4): 427-438, 2018 01 25.
Article in English | MEDLINE | ID: mdl-28967905

ABSTRACT

Deregulated AKT kinase activity due to PTEN deficiency in cancer cells contributes to oncogenesis by incompletely understood mechanisms. Here, we show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and CHK2 activation in response to irradiation, impaired G2 checkpoint proficiency and radiosensitization. These defects are associated with reduced expression of MRE11, RAD50 and NBS1, components of the apical MRE11/RAD50/NBS1 (MRN) DNA damage response complex. Consistent with reduced MRN complex function, PTEN-deficient cells fail to resect DNA double-strand breaks efficiently after irradiation and show greatly diminished proficiency for DNA repair via the error-free homologous recombination (HR) repair pathway. MRE11 is highly unstable in PTEN-deficient cells but stability can be significantly restored by inhibiting mTORC1 or p70S6 kinase (p70S6K), downstream kinases whose activities are stimulated by AKT, or by mutating a residue in MRE11 that we show is phosphorylated by p70S6K in vitro. In primary human fibroblasts, activated AKT suppresses MRN complex expression to escalate RAS-induced DNA damage and thereby reinforce oncogene-induced senescence. Taken together, our data demonstrate that deregulation of the PI3K-AKT/ mTORC1/ p70S6K pathways, an event frequently observed in cancer, exert profound effects on genome stability via MRE11 with potential implications for tumour initiation and therapy.


Subject(s)
Genomic Instability/genetics , MRE11 Homologue Protein/genetics , Neoplasms/genetics , PTEN Phosphohydrolase/deficiency , Recombinational DNA Repair/genetics , DNA Damage/radiation effects , Down-Regulation , Fibroblasts , Gene Expression Regulation, Neoplastic/radiation effects , Genomic Instability/radiation effects , HCT116 Cells , Humans , MRE11 Homologue Protein/antagonists & inhibitors , MRE11 Homologue Protein/metabolism , Mechanistic Target of Rapamycin Complex 1/genetics , Mechanistic Target of Rapamycin Complex 1/metabolism , Neoplasms/radiotherapy , PTEN Phosphohydrolase/genetics , Phosphorylation , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Pyrimidinones/pharmacology , RNA, Small Interfering/metabolism , Radiation Tolerance/genetics , Recombinational DNA Repair/radiation effects , Ribosomal Protein S6 Kinases, 70-kDa/antagonists & inhibitors , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Signal Transduction/genetics , Thiones/pharmacology , X-Rays/adverse effects
4.
Methods Enzymol ; 574: 355-364, 2016.
Article in English | MEDLINE | ID: mdl-27423868

ABSTRACT

Cellular senescence is a state of stable cell cycle arrest triggered by diverse stresses. Establishment of senescence occurs in conjunction with a multitude of chromatin changes, which are just beginning to be studied. These chromatin changes are hypothesized to be causative for senescence. Currently, a preferred method to study such changes is chromatin immunoprecipitation followed by sequencing (ChIP-Seq). This is usually done by cross-linking the cells with formaldehyde and then generating chromatin fragments between 150 and 300bp by sonication. The DNA replication-independent histone chaperone HIRA plays an important role in control of chromatin in nonproliferating senescent cells. While investigating the role of HIRA in senescence, we found conventional ChIP protocols to be problematic, routinely yielding too low amounts of DNA for sequencing. To overcome these problems we adapted and optimized an alternative ChIP method that does not rely on cross-linking and sonication for chromatin fragmentation, and is able to easily isolate chromatin from senescent cells ready for immunoprecipitation. This method uses Benzonase endonuclease for solubilization of uncross-linked chromatin by digestion of DNA and RNA, in the absence of proteolytic activity. Using this protocol, we were easily able to immunoprecipitate HIRA with sufficient DNA for Illumina sequencing.


Subject(s)
Chromatin Immunoprecipitation/methods , Endodeoxyribonucleases/metabolism , Endoribonucleases/metabolism , Epigenomics/methods , Serratia marcescens/enzymology , Animals , Cell Cycle Checkpoints , Cellular Senescence , Chromatin/genetics , Chromatin/metabolism , DNA/genetics , DNA/metabolism , Humans , Sequence Analysis, DNA/methods
5.
Invest New Drugs ; 32(3): 526-34, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24464266

ABSTRACT

INTRODUCTION: Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma. METHODS: We evaluated 32 patients with advanced primary cutaneous or ocular melanoma in a multi-institutional setting (PMH Phase II Consortium) with continuous daily oral vorinostat 400 mg. The primary endpoint was response rate by RECIST, with time to progression as a secondary endpoint. The study was designed to distinguish a response rate of 20 % from a RR of 5 % and to distinguish a 2 month median progression-free survival (PFS), from one of 3.1 months. The study proceeded to stage 2 following 2 of 16 responses.. We also assessed VEGF, FGF levels, P52 polymorphisms and chromatin-associated proteins as potential biomarkers. RESULTS: Therapy was associated with significant side effects, including fatigue, nausea, lymphopenia, and hyperglycemia. Eleven patients experienced at least one grade 3 or higher adverse event. There were two confirmed PRs in patients with cutaneous melanoma. Sixteen patients had stable disease and 14 patients had progressive disease for best response. In addition, two patients with cutaneous melanoma scored as stable disease had early unconfirmed partial responses with subsequent progression. Patients with stable disease or partial response (n = 18) had a median progression free survival of 5 months. (range 2-12 months). CONCLUSIONS: Vorinostat demonstrated some early responses and a high proportion of patients with stable disease, but did not meet its primary endpoint of response. Different schedules of this agent with BRAF mutation status and markers of histone acetylation could be explored in melanoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Histone Deacetylase Inhibitors/therapeutic use , Hydroxamic Acids/therapeutic use , Melanoma/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacology , Biomarkers/blood , Disease-Free Survival , Female , Fibroblast Growth Factors/blood , Histone Deacetylase Inhibitors/adverse effects , Histone Deacetylase Inhibitors/pharmacology , Histones/metabolism , Humans , Hydroxamic Acids/adverse effects , Hydroxamic Acids/pharmacology , Male , Melanoma/genetics , Melanoma/metabolism , Middle Aged , Polymorphism, Single Nucleotide , Skin Neoplasms , Tumor Suppressor Protein p53/genetics , Vascular Endothelial Growth Factor A/blood , Vorinostat , Melanoma, Cutaneous Malignant
6.
Leukemia ; 28(1): 44-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24097338

ABSTRACT

The histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2), a component of the polycomb group complex, is vital for stem cell development, including hematopoiesis. Its primary function, to deposit the histone mark H3K27me3, promotes transcriptional repression. The activity of EZH2 influences cell fate regulation, namely the balance between self-renewal and differentiation. The contribution of aberrant EZH2 expression to tumorigenesis by directing cells toward a cancer stem cell (CSC) state is increasingly recognized. However, its role in hematological malignancies is complex. Point mutations, resulting in gain-of-function, and inactivating mutations, reported in lymphoma and leukemia, respectively, suggest that EZH2 may serve a dual purpose as an oncogene and tumor-suppressor gene. The reduction of CSC self-renewal via EZH2 inhibition offers a potentially attractive therapeutic approach to counter the aberrant activation found in lymphoma and leukemia. The discovery of small molecules that specifically inhibit EZH2 raises the exciting possibility of exploiting the oncogenic addiction of tumor cells toward this protein. However, interference with the tumor-suppressor role of wild-type EZH2 must be avoided. This review examines the role of EZH2 in normal and malignant hematopoiesis and recent developments in harnessing the therapeutic potential of EZH2 inhibition.


Subject(s)
Hematologic Neoplasms/physiopathology , Hematopoiesis/physiology , Polycomb Repressive Complex 2/physiology , Enhancer of Zeste Homolog 2 Protein , Epigenesis, Genetic , Hematologic Neoplasms/pathology , Hematologic Neoplasms/therapy , Humans , Point Mutation , Polycomb Repressive Complex 2/genetics , Polycomb Repressive Complex 2/metabolism , Stem Cells/metabolism
7.
Acta Crystallogr D Biol Crystallogr ; 69(Pt 4): 625-34, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23519671

ABSTRACT

A fast and robust method for determining the parameters for a flat (mask-based) bulk-solvent model and overall scaling in macromolecular crystallographic structure refinement and other related calculations is described. This method uses analytical expressions for the determination of optimal values for various scale factors. The new approach was tested using nearly all entries in the PDB for which experimental structure factors are available. In general, the resulting R factors are improved compared with previously implemented approaches. In addition, the new procedure is two orders of magnitude faster, which has a significant impact on the overall runtime of refinement and other applications. An alternative function is also proposed for scaling the bulk-solvent model and it is shown that it outperforms the conventional exponential function. Similarly, alternative methods are presented for anisotropic scaling and their performance is analyzed. All methods are implemented in the Computational Crystallography Toolbox (cctbx) and are used in PHENIX programs.


Subject(s)
Bioengineering/methods , Computational Biology/methods , Macromolecular Substances/chemistry , Models, Molecular , Algorithms , Anisotropy , Bioengineering/trends , Computational Biology/trends , Crystallography, X-Ray , Macromolecular Substances/metabolism , Normal Distribution , Solvents , Time Factors , X-Ray Diffraction/methods , X-Ray Diffraction/trends
9.
Planta ; 230(3): 589-97, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19526248

ABSTRACT

Chemical imaging by confocal Raman microscopy has been used for the visualization of the cellulose and lignin distribution in wood cell walls. Lignin reduction in wood can be achieved by, for example, transgenic suppression of a monolignol biosynthesis gene encoding 4-coumarate-CoA ligase (4CL). Here, we use confocal Raman microscopy to compare lignification in wild type and lignin-reduced 4CL transgenic Populus trichocarpa stem wood with spatial resolution that is sub-microm. Analyzing the lignin Raman bands in the spectral region between 1,600 and 1,700 cm(-1), differences in lignin signal intensity and localization are mapped in situ. Transgenic reduction of lignin is particularly pronounced in the S2 wall layer of fibers, suggesting that such transgenic approach may help overcome cell wall recalcitrance to wood saccharification. Spatial heterogeneity in the lignin composition, in particular with regard to ethylenic residues, is observed in both samples.


Subject(s)
Cell Wall/metabolism , Lignin/metabolism , Plants, Genetically Modified/metabolism , Populus/metabolism , Plants, Genetically Modified/cytology , Populus/cytology , Spectrum Analysis, Raman
10.
Acta Crystallogr D Biol Crystallogr ; 61(Pt 11): 1514-20, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16239729

ABSTRACT

Automating the determination of novel macromolecular structures via X-ray crystallographic methods involves building a model into an electron-density map. Unfortunately, the conventional crystallographic asymmetric unit volumes are usually not well matched to the biological molecular units. In most cases, the facets of the asymmetric unit cut the molecules into a number of disconnected fragments, rendering interpretation by the crystallographer significantly more difficult. The FINDMOL algorithm is designed to quickly parse the arrangement of trace points (pseudo-atoms) derived from a skeletonized electron-density map without requiring higher level prior information such as sequence information or number of molecules in the asymmetric unit. The algorithm was tested with a variety of density-modified maps computed with medium- to low-resolution data. Typically, the resulting volume resembles the biological unit. In the remaining cases the number of disconnected fragments is very small. In all examples, secondary-structural elements such as alpha-helices or beta-sheets are easily identifiable in the defragmented arrangement. FINDMOL can greatly assist a crystallographer during manual model building or in cases where automatic model building can only build partial models owing to limitations of the data such as low resolution and/or poor phases.


Subject(s)
Algorithms , Crystallography, X-Ray/methods , Macromolecular Substances/chemistry , Alpha-Globulins/chemistry , Cluster Analysis , Electrons , Models, Molecular
11.
Acta Crystallogr A ; 60(Pt 1): 1-6, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14691322

ABSTRACT

The computation of reduced unit cells is an important building block for a number of crystallographic applications, but unfortunately it is very easy to demonstrate that the conventional implementation of cell reduction algorithms is not numerically stable. A numerically stable implementation of the Niggli-reduction algorithm of Krivý & Gruber [Acta Cryst. (1976), A32, 297-298] is presented. The stability is achieved by consistently using a tolerance in all floating-point comparisons. The tolerance must be greater than the accumulated rounding errors. A second stable algorithm is also presented, the minimum reduction, that does not require using a tolerance. It produces a cell with minimum lengths and all angles acute or obtuse. The algorithm is a simplified and modified version of the Buerger-reduction algorithm of Gruber [Acta Cryst. (1973), A29, 433-440]. Both algorithms have been enhanced to generate a change-of-basis matrix along with the parameters of the reduced cell.


Subject(s)
Algorithms , Crystallography
12.
Acta Crystallogr D Biol Crystallogr ; 59(Pt 11): 1966-73, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14573951

ABSTRACT

This paper accompanies a lecture given at the 2003 CCP4 Study Weekend on experimental phasing. The first part is an overview of the fundamentals of Patterson methods and direct methods with the audience of the CCP4 Study Weekend in mind. In the second part, a new hybrid substructure search is outlined.


Subject(s)
Crystallography, X-Ray/methods , Macromolecular Substances , Fourier Analysis , Proteins/chemistry
13.
Acta Crystallogr D Biol Crystallogr ; 59(Pt 11): 1974-7, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14573952

ABSTRACT

This paper accompanies a lecture given at the 2003 CCP4 Study Weekend on experimental phasing. With the audience of the CCP4 Study Weekend in mind, an overview is given of symmetries of substructures and the implications for single isomorphous replacement and single anomalous diffraction phasing procedures, as well as difference Fourier analyses. Pointers are also provided to practical tools for working with substructure symmetries.


Subject(s)
Crystallography, X-Ray/methods , Fourier Analysis
15.
Acta Crystallogr A ; 58(Pt 1): 60-5, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11752765

ABSTRACT

Algorithms for the treatment of special positions in three-dimensional crystallographic space groups are presented. These include an algorithm for the determination of the site-symmetry group given the coordinates of a point, an algorithm for the determination of the exact location of the nearest special position, an algorithm for the assignment of a Wyckoff letter given the site-symmetry group, and an alternative algorithm for the assignment of a Wyckoff letter given the coordinates of a point directly. All algorithms are implemented in ISO C++ and are integrated into the Computational Crystallography Toolbox. The source code is freely available.


Subject(s)
Crystallography, X-Ray/methods , Algorithms , Models, Theoretical , Molecular Conformation
17.
Acta Crystallogr D Biol Crystallogr ; 57(Pt 10): 1390-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11567150

ABSTRACT

This paper presents a review of the principles of molecular replacement with the audience of the CCP4 Study Weekend in mind. A complementary presentation with animated Patterson maps is available online (http://cci.lbl.gov/-rwgk/ccp4sw2001/). The implementation of molecular-replacement methods in the Crystallography and NMR System (CNS) is presented and discussed in some detail. The three principal components are the direct rotation function, Patterson correlation refinement and the fast translation function. CNS is available online and is free of charge for academic users.


Subject(s)
Crystallography , Magnetic Resonance Spectroscopy , Models, Chemical , Models, Molecular , Software
18.
Pest Manag Sci ; 57(8): 695-706, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11517723

ABSTRACT

Cotton and snap bean were selected for a multi-year, multi-state regional (south-eastern USA) research project to evaluate the efficacy of both commercial and experimental bacterial and fungal biological control agents for the management of damping-off diseases. The goal for this portion of the project was to determine the viability and stability of biological agents after application to seed. The biological seed treatments used included: (1) Bacillaceae bacteria, (2) non-Bacillaceae bacteria, (3) the fungus Trichoderma and (4) the fungus Beauveria bassiana. Seed assays were conducted to evaluate the following application factors: short-term (< or = 3 months) stability after seed treatment; quality (i.e. isolate purity); compatibility with chemical pesticides and other biocontrol agents; application uniformity between years and plant species. For the bacterial treatments, the Bacillaceae genera (Bacillus and Paenibacillus) maintained the greatest population of bacteria per seed, the best viability over time and the best application uniformity across years and seed type. The non-Bacillaceae genera Burkholderia and Pseudomonas had the least viability and uniformity. Although Beauveria bassiana was only evaluated one year, the seed fungal populations were high and uniform. The seed fungal populations and uniformity for the Trichoderma isolates were more variable, except for the commercial product T-22. However, this product was contaminated with a Streptomyces isolate in both the years that it was evaluated. The study demonstrated that Bacillaceae can be mixed with Trichoderma isolates or with numerous pesticides to provide an integrated pest control/growth enhancement package.


Subject(s)
Fabaceae/microbiology , Gossypium/microbiology , Pest Control, Biological/methods , Plant Diseases/microbiology , Seeds/drug effects , Bacillaceae/physiology , Burkholderia/physiology , Drug Stability , Mitosporic Fungi/physiology , Pseudomonas/physiology , Seeds/microbiology
19.
Mol Cell Biol ; 21(5): 1854-65, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11238922

ABSTRACT

Substrates of cyclin-cdk2 kinases contain two distinct primary sequence motifs: a cyclin-binding RXL motif and one or more phosphoacceptor sites (consensus S/TPXK/R or S/TP). To identify novel cyclin-cdk2 substrates, we searched the database for proteins containing both of these motifs. One such protein is human HIRA, the homologue of two cell cycle-regulated repressors of histone gene expression in Saccharomyces cerevisiae, Hir1p and Hir2p. Here we demonstrate that human HIRA is an in vivo substrate of a cyclin-cdk2 kinase. First, HIRA bound to and was phosphorylated by cyclin A- and E-cdk2 in vitro in an RXL-dependent manner. Second, HIRA was phosphorylated in vivo on two consensus cyclin-cdk2 phosphoacceptor sites and at least one of these, threonine 555, was phosphorylated by cyclin A-cdk2 in vitro. Third, phosphorylation of HIRA in vivo was blocked by cyclin-cdk2 inhibitor p21(cip1). Fourth, HIRA became phosphorylated on threonine 555 in S phase when cyclin-cdk2 kinases are active. Fifth, HIRA was localized preferentially to the nucleus, where active cyclin A- and E-cdk2 are located. Finally, ectopic expression of HIRA in cells caused arrest in S phase and this is consistent with the notion that it is a cyclin-cdk2 substrate that has a role in control of the cell cycle.


Subject(s)
CDC2-CDC28 Kinases , Cell Cycle Proteins , Cyclin A/metabolism , Cyclin E/metabolism , Cyclin-Dependent Kinases/metabolism , Nuclear Proteins/chemistry , Nuclear Proteins/physiology , Protein Serine-Threonine Kinases/metabolism , Saccharomyces cerevisiae Proteins , Transcription Factors/chemistry , Transcription Factors/physiology , Amino Acid Sequence , Blotting, Western , Cell Cycle , Cell Line , Cell Nucleus/metabolism , Cell Separation , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , Flow Cytometry , Glutathione Transferase/metabolism , Histone Chaperones , Humans , Mass Spectrometry , Microscopy, Fluorescence , Molecular Sequence Data , Nuclear Proteins/metabolism , Peptides/chemistry , Phosphorylation , Plasmids/metabolism , Precipitin Tests , Protein Binding , Recombinant Fusion Proteins/metabolism , Repressor Proteins/chemistry , S Phase , Saccharomyces cerevisiae/metabolism , Sequence Homology, Amino Acid , Threonine/chemistry , Transcription Factors/metabolism , Transfection
20.
Biochim Biophys Acta ; 1471(3): M123-33, 2001 Mar 21.
Article in English | MEDLINE | ID: mdl-11250068

ABSTRACT

The retinoblastoma tumor suppressor protein (pRB) is a paradigm for understanding cell cycle- and proliferation-dependent transcription and how deregulation of this process contributes to the neoplastic process in humans. The ability of pRB to regulate transcription, and consequently cell proliferation and differentiation, is regulated by the activity of cyclin/cdks. In general, phosphorylation of pRB by cyclin/cdks inactivates pRB-mediated transcriptional inhibition and growth suppression. However, it is apparent that pRB is a multi-functional protein that can inhibit transcription through various mechanisms. This review focuses on recent data to suggest that different pRB functions are progressively and cooperatively inactivated by multiple cyclin/cdk complexes during G1- and S-phase. The implications of such a model for pRB-mediated tumor suppression are discussed.


Subject(s)
CDC2-CDC28 Kinases , Cyclins/pharmacology , Nuclear Proteins/genetics , Proto-Oncogene Proteins , Retinoblastoma Protein/genetics , Animals , Binding Sites , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinases/chemistry , Cyclin-Dependent Kinases/pharmacology , Gene Expression Regulation, Neoplastic , Humans , Nuclear Proteins/chemistry , Phosphorylation , Protein Serine-Threonine Kinases/chemistry , Protein Serine-Threonine Kinases/pharmacology , Retinoblastoma Protein/antagonists & inhibitors , Retinoblastoma Protein/chemistry , Retinoblastoma-Like Protein p107
SELECTION OF CITATIONS
SEARCH DETAIL
...